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Abstract
Fifty-eight consecutive children with high-risk malignancies were treated with cyclophosphamide 
and targeted topotecan followed by autologous hematopoietic cell transplantation (AHCT) in a 
phase I/II IRB-approved study. Twelve participants enrolled in phase I; 5 received dose level 1 of 
topotecan 3mg/m2/day with subsequent doses targeted to total systemic exposure of 100 ± 20 ng
°hr/ml and cyclophosphamide 750mg/m2/day. Seven participants received dose level 2. 
Cyclophosphamide dose escalation to 1g/m2/day was considered excessively toxic; 1 died from 
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irreversible veno-occlusive disease and 2 experienced reversible hepatotoxicity. These adverse 
events halted further dose escalation. Forty-six participants were enrolled in phase II; results are 
on the 51 participants who received therapy at dose level 1, the maximum tolerated dose. 
Diagnoses included neuroblastoma (26), sarcoma (9), lymphoma (8), brain tumors (5), Wilms (2) 
and retinoblastoma (1). Twenty participants (39.3%) were in ≥ CR1 at enrollment; median age was 
5.1 years. Most common non-hematologic grade 3/4 toxicity was gastrointestinal (n=37). 
Neutrophil and platelet engraftment occurred at a median of 15 and 24 days, respectively. Twenty-
six (51%) remain alive at a median of 6.4 years after AHCT. Cyclophosphamide 3.75g/m2 and 
targeted topotecan followed by AHCT is feasible and produces acceptable toxicity in children with 
high-risk malignancies.
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INTRODUCTION
Autologous hematopoietic cell transplantation (AHCT) is used as consolidation therapy to 
treat patients with high-risk malignancies; however, only a fraction of these patients are 
cured with the majority developing recurrent disease.
1, 2 Clinical and laboratory studies 
support dose intensification as a strategy for improving survival for adults and children with 
malignancies at high risk of treatment failure. In our preclinical xenograft model system and 
in phase I and II trials, topotecan has shown promising anti-tumor activity in several 
pediatric malignancies such as neuroblastoma, rhabdomyosarcoma, CNS tumors, and Wilms 
tumor.
3-7 Results of a Pediatric Oncology Group phase I trial identified the maximum 
tolerated dose (MTD) for topotecan (0.75 mg/m2/d) and cyclophosphamide (250 mg/m2/d) 
when each was given once daily for five consecutive days without stem cell rescue but 
followed by filgrastim.
8
 No significant toxicity other than myelosuppression was identified, 
and responses were observed in osteosarcoma, neuroblastoma, Wilms tumor, and 
rhabdomyosarcoma. The broad anti-tumor activities of this combination in lower doses 
made it ideal to consider escalation to higher doses with AHCT.
Doses up to 7 g/m2 of cyclophosphamide have been given in combination with maximum 
doses of etoposide (a topoisomerase II inhibitor) followed by stem cell rescue, with 
acceptable toxicity. Therefore, cyclophosphamide 3.75 g/m2 combined with topotecan was 
considered safe for study in the setting of autologous stem cell rescue. In children with 
recurrent solid tumors, researchers at St. Jude Children’s Research Hospital in Memphis, 
Tennessee completed a phase I trial of topotecan, 10 doses delivered with dose adjustments 
to a targeted systemic exposure (TSE) of 100 ng°hr/ml. In another St. Jude trial for 
metastatic neuroblastoma, researchers successfully targeted the topotecan dose in 22 of 27 
days (81%), but more importantly attained the targeted topotecan AUC in each patient 
studied. 
9
 Based on this experience, a phase I/II dose escalation study using ten doses of 
topotecan and five doses of cyclophosphamide followed by AHCT in children with high-risk 
malignancies was proposed.
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Patients with solid tumor and lymphomas at high-risk of treatment failure were eligible. 
Additional eligibility criteria included age < 25 years at diagnosis, ECOG performance score 
0-2, ANC > 750/mm3, echocardiographic shortening fraction > 25%, BUN < 40 mg/dl, 
creatinine < 2.0 mg/dl, bilirubin < 3.5 mg/dl and SGOT < 500 U/dl. All patients had 
documented chemotherapy-responsive disease and were greater than 2 weeks from previous 
therapy and had recovered from toxicity. The St. Jude Institutional Review Board approved 
this clinical trial, and participants and/or legal guardians provided informed consent prior to 
the initiation of the preparative regimen.
Toxicity Grading
Toxicities were collected prospectively by a clinical research nurse for the first 100 days 
after transplantation and followed for resolution; a transplant physician concurrently 
reviewed all toxicities and assigned level of severity and attribution to the treatment regimen. 
All cases of non-hematologic organ dysfunction were considered regimen-related toxicities 
(RRT). Toxicities were scored according to the National Cancer Institute (NCI) Common 
Toxicity Criteria Version 2.0.
10
 An external Data Safety Monitoring Board was not used for 
this trial; rather the study’s investigators discussed and monitored the toxicities internally.
Study Design and Analysis
The trial was originally designed to study 4 dosage levels in the phase I portion of the study:
Level 1: cyclophosphamide dosage 3.75 grams/m2; targeted topotecan to 100 ± 20 ng
°hr/ml;
Level 2: cyclophosphamide dosage 5 grams/m2; targeted topotecan to 100 ± 20 ng
°hr/ml;
Level 3: cyclophosphamide dosage 5 grams/m2; targeted topotecan to 140 ± 20 ng
°hr/ml;
Level 4: cyclophosphamide dosage 5 grams/m2; targeted topotecan to 160 ± 20 ng
°hr/ml.
The objectives of this trial in defining the maximum tolerated dose (MTD) were assessed 
according to a traditional phase I study. MTD was defined as the dose level below the 
unacceptable dose limiting toxicity (DLT) level. A DLT was defined as an irreversible 
toxicity, present at the time of death, or reversible non-hematologic grade IV toxicity that 
persisted for greater than 10 days. Any participant who had not engrafted by day 45 post-
transplantation was also considered a failure.
Once the MTD was determined, the phase II portion of the study began with the aim to 
better understand the toxicity profile due to this regimen. This portion of the study was set 
up using a Simon’s two-stage design to try and insure that not many patients were on a toxic 
chemotherapy preparative regimen.
11
 Those in the MTD cohort in phase I were included in 
the phase II part of the study. Although the study was originally written to enroll up to an 
additional 19 patients at the MTD, because stopping rules had not been met and there was no 
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subsequent protocol for these patients, IRB approval was obtained to continue enrollment on 
study. Hence, 51 participants were enrolled and treated on dose level 1.
Survival was defined as the time interval from date of transplant to death from any cause or 
to last follow-up. For event-free survival (EFS), an event was defined as a relapse, disease 
progression, or death (due to any cause). The date of the first event was used in calculating 
EFS. For this survival analysis, time was censored at the last follow-up date if no failure was 
observed. Kaplan-Meier survival estimates were obtained and the comparisons between 
survival distributions were made using the log-rank test.
12-13
The cumulative incidence of relapse was estimated by the method of Kalbfleisch and 
Prentice (1980) which accounts for competing risks.
14
 The length of time at risk for relapse 
was computed from the date of AHCT to the date of relapse, death, or last contact, 
whichever came first. Deaths from non-relapse causes were considered as competing events. 
The cumulative incidences of relapse for different diagnosis group were compared by Gray’s 
test
15
. The criteria for significance for all analyses were a p-value significant at a level of 
α=0.05. All statistical analyses used SAS Release 9.2.
Disease status, such as complete remission, very good partial response, partial response, 
stable disease, and progressive disease, was not defined by this study. Participant’s disease 
response was categorized as determined by the participant’s induction chemotherapy.
Stem Cell Collection and Cryopreservation
All patients had marrow morphologically free of tumor at the time of peripheral blood stem 
cell collection or marrow harvest. PBSC collection was performed after routine 
chemotherapy administration followed by G-CSF 10 mcg/kg/day until apheresis was 
completed. PBSC collection goal was at least 2 × 106 CD34+ cells/kg. A marrow harvest 
was performed in patients unable to mobilize stem cells; targeted marrow cell dose was 
greater than 1.0 × 108 total nucleated cells/kg. Two patients had stem cell products purged 
on another institutional protocol using CD34+ positive selection and FACS analysis. A 
minimum of 1 × 106 CD34+ cells/kg from an apheresis product or 1 × 108 total nuclear 
cells/kg from a marrow product was required to proceed to AHCT. All stem cell products 
were stored at −150° C in the vapor phase of liquid nitrogen using 10% dimethylsulfoxide 
(DMSO) and a controlled rate freeze program.
Conditioning Regimen
For the Phase I portion of the study, topotecan was administered intravenously once daily as 
a 30-minute infusion for 10 days (Days −11 to −2). At levels 1 and 2, patients initially 
received topotecan 3 mg/m2/day with subsequent dosages adjusted to achieve a targeted 
topotecan lactone AUC (area under the concentration-time curve) value of 100 ± 20 ng
°hr/ml.
16
 Dosages of chemotherapeutic agents were calculated using actual body weight. All 
patients but one received full-prescribed doses of each agent.
On days −6 through −2, cyclophosphamide was infused intravenously over 1 hour according 
to the dose escalation schedule. At level 1, patients also received cyclophosphamide 750 
mg/m2/day for 5 days (total 3.75grams/m2). Mesna at 25% of the cyclophosphamide dose 
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was administered intravenously prior to each dose of cyclophosphamide and again at 3, 6, 
and 9 hours after each dose of cyclophosphamide, equaling 100% of the cyclophosphamide 
dose. At level 2, cyclophosphamide was administered at a dose of 1000 mg/m2/day for 5 
days (total 5 grams/m2). Patients began pre-hydration with D5W + 0.45% Sodium Chloride 
at 125 ml/m2/hr at the time of admission to the inpatient transplant unit on day −7, the 
evening prior to the first dose of cyclophosphamide. This intravenous fluid rate continued 
until day 0, the day of the stem cell infusion. Day −1 was a rest day. Prior to stem cell 
infusion on day 0, the graft was rapidly thawed in a 37° C water bath at the bedside and then 
infused through a central venous catheter. On day +1, filgrastim (G-CSF) was given at 5 
μg/kg/day subcutaneously or intravenously until ANC > 3000/mm3 on 2 consecutive days. 
No prophylaxis for veno-occlusive disease of the liver was administered.
Pharmacokinetics
For each patient, blood samples were obtained prior to the topotecan infusion, and at 0.25, 1, 
and 6 hours after the end of the topotecan infusion on days −6 and −11. Each sample was 
processed immediately, and topotecan lactone concentrations were measured by high 
performance liquid chromatography.
16
 Topotecan lactone systemic clearance and single day 
AUC were calculated for each patient. If the single day topotecan lactone AUC was within 
the targeted AUC range on day-11 or day-6, then no dosage adjustment was required on the 
subsequent day and the patient remained at the same topotecan dosage. If the single day 
topotecan lactone AUC was not within the targeted topotecan AUC range on day-11 or 
day-6, the subsequent topotecan dosage was adjusted based on that patient’s topotecan 
lactone clearance, to attain a single day topotecan lactone AUC in the targeted range.
If the topotecan target AUC range was not achieved with the dosage adjustment on day-10 or 
−5, additional dosage adjustments were made until the target was achieved. If topotecan 
blood samples or pharmacokinetic studies were not evaluable, then blood samples were 




Fifty-eight patients with high-risk solid malignancies were enrolled on this Institutional 
Review Board- approved study. Twelve patients received therapy on the phase I portion.. 
Five received dose level 1 (topotecan target AUC of 100 ± 20 ng°hr/ml and 
cyclophosphamide 750 mg/m2/day × 5 days). One of the 5 participants experienced a dose-
limiting toxicity, stomatitis. Seven patients were treated at dose level 2 (topotecan target of 
100 ± 20 ng°hr/ml and cyclophosphamide 1000 mg/m2/day × 5 days). One dose level 2 
patient experienced an irreversible grade IV non-hematologic regimen- related-toxicity and 
eventually died of veno-occlusive disease. Two other participants experienced grade 2 
hyperbilirubinemia and were clinically diagnosed with mild veno-occlusive disease. 
Although these 2 events did not meet stopping rule guidelines, for the safety of the patients, 
the principal investigator in collaboration with other study team members, including the 
study’s biostatistician and co-investigators, decided to close the phase I safety portion of the 
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study. Dose level 1 was deemed the MTD. Characteristics dose level 2 participants are 
described in Table 1. Three participants died from primary disease. The next 46 consecutive 
patients were treated on the trial’s phase II portion at dose level 1. Results will be described 
based on the 51 patients who received therapy at dose level 1 (5 from phase I and 46 from 
phase II). Patient demographics for these participants, including diagnoses, disease status at 
the time of AHCT are outlined in Table 2.
Regimen-Related Toxicities
Fifty of the 51 participants were able to receive full doses of the preparative regimen. One 
patient with NHL was only able to received 9 of 10 doses of topotecan and 3 of 5 doses of 
cyclophosphamide. This participant developed premature ventricular contractions with short 
runs of ventricular tachycardia and further chemotherapy was omitted. The patient, who had 
no previous history of cardiac disease and had a normal echocardiogram and 
electrocardiography prior to the initiation of this therapy, remained hemodynamically stable, 
had no electrolyte abnormalities, and did not require medical intervention. Although there 
was also a high incidence of other Grade III-IV toxicity in this heavily pretreated population 
(Table 3), three patients had no Grade III-IV non-hematologic toxicity. Toxicities were 
reviewed in real time at transplant research meetings and determined to be acceptable and 
expected in the setting of high dose chemotherapy followed by stem cell rescue, particularly 
gastrointestinal toxicities (Table 4). Due to these expected toxicities, de-escalation below 
level 1 was not considered. Three patients (5.9%) died of non-relapse toxicity, including 
multi-system organ failure and respiratory failure.
Transplant outcome
All patients achieved neutrophil engraftment, defined as the first day of 3 consecutive days 
with an ANC > 0.5 × 109/l, at a median of day +15 (range, 8-33 days) and platelet 
engraftment, defined as platelets > 20,000/μl without transfusion for seven consecutive days, 
at a median of day +24 (range, 8-109 days). The median time to neutrophil engraftment for 
patients receiving marrow grafts was day +18 (range, 10-33 days) and for those receiving 
PBSC grafts day +10 (range, 8-11 days) (p < 0.0001). The median time to platelet 
engraftment for marrow recipients was day +27 (range, 16-109 days) while those receiving 
PBSC grafts achieved platelet engraftment at a median of day +17.5 (range, 8-88 days) (p = 
0.001). The 3-year and 5-year overall survival (OS) for the 51 participants was 66.7 ± 6.5% 
and 58.7 ± 7.7% respectively (Figure 1). The 3-year and 5-year event-free survival (EFS) 
were 43.1 ± 6.8% and 41.2 ± 8.2% respectively (Figure 1). The cumulative incidence of 
relapse for all participants was 54.9 ± 7.1 at 3 years and 56.9 ± 7.1 at 5 years (Figure 2A). 
Although not statistically significant (for all diagnoses, p-value = 0.83) (Figure 2B), 
neuroblastoma (the most common tumor in this study) showed a tendency of being more 
likely to relapse at both 3 and 5 years (57.7 ± 10.0% and 61.5 ± 9.9%, respectively) 
compared to lymphomas (50.0 ± 19.4% and 50.0 ± 19.4%, respectively) or sarcomas (44.4 
± 17.9% and 44.4 ± 17.9%, respectively). Upon univariate analysis of OS and EFS in 
respects to gender, product infused, diagnosis, and disease status prior to AHCT, none of 
these variables were statistically significant (data not shown). Twenty-two patients (43.2%) 
died of recurrent, persistent, or progressive disease; 2 (3.9%) died from multi-organ failure 
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and 1 (2%) died from respiratory failure. Twenty-six participants (51%) are surviving at a 
median follow-up time of 6.4 years (range, 4.0-9.8 years).
Pre- and Post-transplant Therapy
Four patients received radiation therapy before AHCT, four received radiation after AHCT 
and five received radiation therapy both before and after AHCT. Three patients with 
neuroblastoma received post-transplant therapy with cis-retinoic acid beginning at a median 
of 32 days post-AHCT (range, 32-53 days) and continuing for 6 months as directed by their 
primary treatment plan. No patient received anti-tumor antibody therapy post-HSCT.
Topotecan Pharmacokinetics
The median (range) topotecan lactone clearance was 32.1 L/hr/m2 (range 15.3 to 44.2). A 
total of 138 pharmacokinetic studies were performed in 55 patients during cycle 1. All 
patients received a fixed 3 mg/m2 fixed topotecan dosage for the first dose of cycle 1, and of 
the 55 studies 39 (71%) were within the desired target range. Of the remaining 83 
pharmacokinetic studies, 67 were within the target range for a pharmacokinetic targeting 
success of 81%. The median (range) topotecan dosage for the patients that were within the 
target range was 3.1 mg/m2 (1.1 to 4.6). Those studies outside the target range were evenly 
distributed among participants and after a second study, all patients were within the target 
range. No difference in topotecan pharmacokinetics or targeting results was noted between 
those patients receiving cyclophosphamide 750 or 1000 mg/m2.
DISCUSSION
In the past 25 years, the prognosis for pediatric solid tumors has improved largely because of 
a multi-modal approach including multi-agent chemotherapy regimens, aggressive surgery, 
and conformal radiation therapies. However patients with metastatic or recurrent disease 
often have a dismal prognosis and are candidates for aggressive therapy including AHCT. 
Although neuroblastoma is the only pediatric malignancy in which randomized studies have 
demonstrated an increase in survival rate with the addition of AHCT to the treatment schema 
compared to standard chemotherapy alone, this treatment is frequently used to treat other 
high-risk pediatric solid tumors such as Ewing sarcoma, rhabdomyosarcoma, Wilms tumor, 
and lymphomas.
17-21 Topotecan has shown promising anti-tumor activity in pediatric 
malignancies, such as neuroblastoma, rhabdomyosarcoma, Wilms tumor, retinoblastoma, 
and Ewing sarcoma.
22-24 In a Children’s Oncology Group trial in which 119 patients with 
relapsed or refractory neuroblastoma were randomized to receive either topotecan alone (2 
mg/m2/day for 5 days) or in combination with cyclophosphamide (topotecan 0.75 
mg/m2/day with cyclophosphamide 250 mg/m2/day for 5 days), the two-drug combination 
demonstrated superior outcomes in terms of progression-free survival, but no difference in 
overall survival.
3
Combining alkylating agents with topoisomerase inhibitors is attractive because of the broad 
activity in pediatric malignancies and the non-overlapping extramedullary toxicities. 
Gastrointestinal, fever/neutropenia, metabolic disturbances, and skin abnormalities were the 
most common Grade III-IV toxicities observed. Skin toxicities were common in areas that 
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had received prior radiation therapy as well as in non-radiated regions.
25
 Topotecan is 
known to be a radiosensitizing agent, suggesting these skin toxicities were a form of 
radiation recall.
26,27 One patient each who had received thoracic radiation therapy developed 
cardiac arrhythmias or pleuro-pericardial effusions.
Three patients died of non-relapse causes, including multi-system organ failure and single 
organ failure. This toxicity rate is lower compared to those reported in other series of AHCT 
in pediatrics.
28
 The reminder of those who died in this trial experienced progressive or 
recurrent disease. This is consistent with the results of prior studies in which disease 
recurrence has remained the main cause of treatment failure after AHCT.
29
 VOD and liver 
toxicity have not been observed frequently with topotecan, but was the most common 
toxicity leading to the determination of the MTD.
30,31 Cyclophosphamide may have also 
contributed to the observed hepatotoxicity as this side effect has been well described 
32, 33 
and the participants were heavily pre-treated prior to AHCT. Topotecan, on the other hand, 
has not been studied extensively as a component of transplant regimens. The majority of 
published experience is in the setting of high-risk or recurrent ovarian cancer or multiple 
myeloma, used in combination with other agents.
34-37 For patients with CNS tumors, 
topotecan (2 mg/m2/day for 5 days) was given with thiotepa (300 mg/m2/day for 3 days) and 
carboplatin (approximating 500 mg/m2/dose for 3 days, with Calvert formula under the 
curve 7) to 10 patients.
38
 There were two toxic deaths and 4 were surviving disease free at a 
median of 6 years after treatment. Other trials using topotecan-containing regimens with and 
without stem cell support demonstrate feasibility and therapeutic efficacy in patients with 
leukemias, lymphomas, and other solid tumors in children and adults.
39-44 These studies 
have demonstrated acceptable response rates to the treatment regimen. Toxicities in these 
studies were similar to ours but cutaneous toxicity was not commonly observed. It is 
important to note that this study was the only one to target topotecan doses and the only one 
to include pediatric patients. Other published studies primarily included adult patients with 
non-pediatric malignancies, a markedly different population than this study.
Five-year event-free-survival (EFS) for all patients on this study was 41.2% which compares 
favorably with the literature as these were high-risk diseases. Mesenchymal tumors, such as 
sarcomas had promising results with the 5-year EFS being 44.4%, suggesting this regimen 
merits further study in this cohort. In addition, patients with lymphoma demonstrated 
responses (5-year EFS 50%), but patient numbers were quite low. Additional studies are 
needed in this group to better categorize efficacy. For patients with neuroblastoma, it is 
important to note that none of these patients received post-transplant antibody therapy. 
Overall survival rates at 5-years were favorable allowing patients to proceed to other salvage 
therapies. This observation suggests that this regimen is well tolerated and does not lead to 
long-term organ dysfunction and prohibiting further relapse therapies.
In this study, the MTD dose was determined to be 3 g/m2 cyclophosphamide and ten doses 
of topotecan with a TSE of 100 ± 20 ng°hr/ml when administered with hematopoietic stem 
cell rescue. Topotecan administration was easily administered on an outpatient basis, 
although early admissions were necessary due to fever in some patients. Our study 
demonstrates the feasibility and relative safety of this combination of cyclophosphamide and 
topotecan. Future efforts may be directed at increasing the dose of topotecan or 
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incorporating an additional agent into the regimen. As has been demonstrated in other 
malignancies, most notably acute lymphoblastic leukemia, individualized drug treatment 
may enhance treatment efficacy while reducing toxicity.
45, 46
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Overall survival and event-free survival of the 51 participants and the number at risk treated 
on dose level 1.
Kasow et al. Page 12














Kasow et al. Page 13















A. Cumulative incidence of relapse among the 51 participants treated on dose level 1. B. 
Cumulative incidence of relapse by disease type and the number at risk. No statistical 
significance among disease type (p-value = 0.83). Neuroblastoma (NB), lymphoma, and 
sarcoma were the 3 most common diagnoses treated in this study. The others category 
included brain tumor, Wilms tumor, and retinoblastoma.
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Table 1












1 14.9 Male LYMPHOMA PD PBSC
















5 1.8 Male NB VGPR BM
6 14.4 Male SARCOMA PR PBSC Hyperbilirubinemia*




Abbreviations: HCT, hematopoietic cell transplantation; NB, neuroblastoma; PD, progressive disease; CR, complete remission; VGPR, very good 
partial response; PR, partial response; PBSC, peripheral blood stem cell; BM, bone marrow; DLT, dose limiting toxicity; VOD, veno-occlusive 
disease; MSOF, multi-system organ failure.
*
Hyperbilirubinemia was determined to be a dose limiting toxicity by the study’s principal investigator in collaboration with study co-investigators, 
biostatisticians, and other team members.
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Table 2
Patient characteristics of the 51 participants who received the preparative regimen at dose Level 1.
N %
Gender
 Female 24 47.1
 Male 27 52.9
Age at Transplant Mean±Std Dev Median (min-max)
7.6 ± 6.0 5.1 (1.5 – 21.3)
Diagnosis at Transplant
 NEUROBLASTOMA 26 51.0
 LYMPHOMA 8 15.7
 SARCOMA 9 17.7
 BRAIN TUMOR 5 9.8
 WILMS TUMOR 2 3.9
 RETINOBLASTOMA 1 2.0
Disease Status at Transplant
 CR1 11 21.6
 CR2 7 13.7
 CR3 1 2.0
 CR4 1 2.0
 PD 2 3.9
 PR 8 15.7
 Rel 1 2 3.9
 SD 10 19.6
 VGPR 9 17.6
Product Type
 BM 33 64.7
 PBSC 18 35.3
Abbreviations: BM, bone marrow; PBSC, peripheral blood stem cell; CR, complete remission; PD, progressive disease; PR, partial response; Rel, 
relapse; SD, stable disease; VGPR, very good partial response; Std Dev, standard deviation.
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Table 3
Maximum grades 1-4 adverse events divided by category.
+
 The relationship of the adverse event to the study 
was defined as definite, possible, probable, or remote. The numbers in the cells represent the number of 
participants who experienced this maximum grade adverse event and the total number of participants who 
experienced an adverse event in the specific category.
CATEGORY
MAXIMUM GRADE
TOTAL1 2 3 4
ALLERGY/IMMUNOLOGY 1 5 2 0 8
AUDITORY/HEARING 2 0 1 0 3
APPENDIX VI BMT EVENTS 0 0 2 0 2
BLOOD/BONE MARROW 0 4 10 2 16
CARDIOVASCULAR
(ARRHYTHMIA) 1 2 0 0 3
CARDIOVASCULAR
(GENERAL) 2 7 5 1 15
CONSTITUTIONAL SYMPTOMS 13 10 3 0 26
DERMATOLOGY/SKIN 4 10 14 0 28
ENDOCRINE 0 2 1 0 3
GASTROINTESTINAL 3 6 9 28 46
HEMORRHAGE 6 0 8 1 15
HEPATIC 2 4 9 1 16
INFECTION/FEBRILE
NEUTROPENIA 1 5 32 0 38
METABOLIC/LABORATORY 0 4 16 2 22
NEUROLOGY 3 1 2 0 6
PAIN 4 7 12 0 23
PULMONARY 2 2 9 2 15
RENAL/GENITOURINARY 5 9 3 0 17
+
AEs were coded according to the Common Toxicity Criteria, version 2.0.













Kasow et al. Page 18
Table 4
Grades 3 and 4 adverse events. The numbers represent the number of patients who experienced this particular 
adverse event of the indicated grade. For example, among the 51 patients in the analysis sample, 1 experienced 
grade 3 “Allergic Reaction, Blood Products”, no one experienced grade 4 of this event.
CATEGORY Grade Grade
 Adverse event 3 4
ALLERGY/IMMUNOLOGY
 Allergic Reaction, Blood Products 1 0
 Allergic Reaction, Bone Marrow Infusion 1 0
AUDITORY/HEARING
 Otitis media 1 0
Appendix VI BMT Events
 Veno-occlusive disease of the liver 2 0
Blood/Bone Marrow
 Anemia 2 1
 Leukopenia 1 1
 Neutropenia 3 0
 Thrombocytopenia 2 0
 Transfusion, packed red blood cells 4 0
 Transfusion, platelets 6 0
CARDIOVASCULAR (GENERAL)
 Hypertension 1 0
 Hypotension 4 1
CONSTITUTIONAL SYMPTOMS
 Fever without Neutropenia 3 0
DERMATOLOGY/SKIN
 Cellulitis 1 0
 Desquamation 1 0
 Pruritus 1 0
 Rash 11 0
 Rash, Generalized 1 0
 Skin Excoriation, Hickman Line Site 1 0
 Urticaria 1 0
ENDOCRINE




 Colitis 3 0
 Dehydration 1 0
 Diarrhea 12 0
 Esophagitis 1 0
 Loss of Appetite 1 27
 Mucositis 2 0
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CATEGORY Grade Grade
 Adverse event 3 4
 Nausea 2 0
 Pancreatitis 1 0
 Stomatitis 1 1
 Stomatitis and Pharyngitis 0 1
 Typhlitis 7 0
 Vomiting 3 0
HEMORRHAGE
 Epistaxis 4 0
 Hematuria 3 0
 Hemorrhagic Cystitis 3 1
HEPATIC
 Alanine Aminotransferase, Abnormal Level 1 1
 Aspartate Aminotransferase, Abnormal Level 2 1
 GGT, Abnormal Level 1 0
 Hepatomegaly 4 0
 Hyperbilirubinemia 2 0
 LDH, Abnormal Level 1 0
 SGPT Measurement, Abnormal Level 1 0
INFECTION/FEBRILE NEUTROPENIA
 Febrile Neutropenia 26 0
 Infection, Adenovirus, Stool 4 0
 Infection, Candida, Rectum 2 0
 Infection, Candida, urine 1 0
 Infection, Clostridium Difficile, Stool 1 0
 Infection, Coagulase Neg Staph, Nares 1 0
 Infection, E. Coli, Blood 1 0
 Infection, Enterobacter, Blood/Hickman Line 1 0
 Infection, Fungal, Disseminated 1 0
 Infection, Gamma-hemolytic Strep, Blood 1 0
 Infection, Herpes zoster dermatitis 1 0
 Infection, Human Herpes Simplex Virus, Oral 2 0
 Infection, Pseudomonas, Stool 2 0
 Infection, Staphylococcus Epidermidis, Blood 1 0
 Infection, Staphylococcus, Hickman Catheter 1 0
METABOLIC/LABORATORY
 Amylase Measurement, Abnormal Level 1 0
 Hyperglycemia 4 0
 Hyperuricemia 1 0
 Hypocalcemia 1 0
 Hypokalemia 16 3
 Hypophosphatemia 6 0
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CATEGORY Grade Grade
 Adverse event 3 4
 Lipase Measurement, Abnormal Level 1 0
NEUROLOGY
 Hallucinations 2 0
PAIN
 Abdominal Pain 6 0
 Headache 1 0
 Pain, Back 1 0
 Pain, Generalized, Multiple Sites 3 0
 Pain, Skin 1 0
 Pain, radiation related 1 0
PULMONARY
 Dyspnea 1 0
 Hypoxia 4 1
 Infiltrates, Pulmonary 0 1
 Pleural effusion 3 0
 Pneumonia 3 1
 Pneumonitis 1 0
 Pulmonary Nodules 1 0
 Pulmonary edema 1 0
RENAL/GENITOURINARY
 BUN, elevated 1 0
 Renal failure 1 0
 Spasm, Bladder 1 0
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